secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001558370-24-008140
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Neurosciences Q1 net loss $3.6M; cash $2.5M; Phase 1a data on track for mid-2024
--------------------------------------------------------------------------------

- Cash and equivalents $2.5M at March 31, 2024, down from $12.6M at Dec 31, 2023.
- Net loss $3.6M in Q1 2024 versus $5.0M in Q1 2023; R&D $2.1M, G&A $1.6M.
- Phase 1a PMN310 top-line data expected mid-2024; Phase 1b planned H2 2024 subject to resources.
- Neil Warma appointed interim CEO in January 2024, continues as CEO and director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837024008140/0001558370-24-008140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837024008140/pmn-20240514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-008140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer